USA

200 mg Limit to Hydroxychloroquine Tablets Challenging for SLE Patients

200 mg Limit to Hydroxychloroquine Tablets Challenging for SLE Patients

One-quarter of systemic lupus erythematosus patients in the U.S. taking hydroxychloroquine tablets daily are exceeding the recommended doses for this treatment, and up to one-third of those on alternate-day treatment are forgetting or mixing up their medication, a study reports.

The problem, researchers say, is that only 200 mg tablets exist – and many patients are prescribed a 300 mg dose. New dosage forms are needed to ensure proper treatment, researchers recommend.

Non-pharmacologic therapies for systemic lupus erythematosus

Non-pharmacologic therapies for systemic lupus erythematosus

Physical Exercise and Psychological Interventions Complement Usual Medical Care in Lupus.

Over the last two decades more research has been conducted which looks at non pharmacological therapies as a potential adjunct (add on) treatment to relieve lupus symptoms such a pain, fatigue, depression, quality of life and disease activity. Researchers in a new study conducted an updated literature review to bring together major findings and allow for some conclusions to be drawn.

Researchers identify early indicators of pregnancy complications in lupus patients

Researchers identify early indicators of pregnancy complications in lupus patients

A study of pregnant women with systemic lupus erythematosus has identified early changes in the RNA molecules present in the blood that could be used to determine the likelihood of them developing preeclampsia.

The study, which is published in the Journal of Experimental Medicine, may also help researchers develop treatments to prevent other pregnancy complications associated with lupus, including miscarriage and premature birth.

Study of Childhood Onset Lupus Confirms Unique Needs of Adolescents and Young Adults

Study of Childhood Onset Lupus Confirms Unique Needs of Adolescents and Young Adults

Childhood-onset systemic lupus erythematosus (cSLE) accounts for 10-20 percent of all people living with lupus. Understanding the living experience of adolescents and young adults (AYAs) with cSLE is an important first step in developing interventions to aid in self-management and adherence.

A new study surveyed AYAs from a Midwestern children’s hospital with cSLE between the ages of 12 and 24, and 44 primary caregivers, about living with lupus.

Restoring this enzyme's function protects against heart disease in lupus

Restoring this enzyme's function protects against heart disease in lupus

Patients with lupus, an inflammatory disease in which the body's immune system attacks its own tissues, are on average seven to nine times more likely to develop heart disease than the general population. Younger women with lupus are 50 times as likely to develop the disease as young women without the disease.

The endothelium -- the single layer of cells lining blood vessel walls -- is thought to protect against heart disease. It does so in part by producing nitric oxide.

Genetically engineered immune cells wipe out lupus in mice

Genetically engineered immune cells wipe out lupus in mice

Lupus can be a stubborn disease to treat. Although many struck by the autoimmune condition live relatively normal lives, some suffer from kidney failure, blood clots, and other complications that can be deadly. Now, scientists have found that a novel treatment that wipes out the immune system’s B cells cures mice of the condition. Though the work is preliminary, it has excited researchers because it uses a therapy already approved for people with blood cancer.

“This is a critical stepping stone,” says Jennifer Anolik, a rheumatologist who runs the lupus clinic at the University of Rochester Medical Center in New York who was not involved with the work.

Study Identifies Potential New Targets for Improving Heart Health in People with Lupus

Study Identifies Potential New Targets for Improving Heart Health in People with Lupus

People with lupus and rheumatoid arthritis (RA) have a greater risk of developing cardiovascular diseases (CVD) and atherosclerosis. A new study conducted in Columbia has identified potential new therapeutic targets for reducing endothelial damage (defined as the destruction of the membrane that lines the inside of the heart and blood vessels).

Kidney transplant boosts survival in lupus nephritis

Kidney transplant boosts survival in lupus nephritis

Patients with LN-ESRD have high mortality rates, Dr. April Jorge of Massachusetts General Hospital in Boston, MA, noted in an email to Reuters Health.

"We found that among nearly all such patients in the US who were waitlisted, renal transplant was associated with a significant survival benefit," she said. "This is an encouraging finding, and clinicians should consider early referral for renal transplantation for patients with LN-ESRD who may be candidates, as this can reduce mortality."

Resunab, a promising future treatment for lupus.

Resunab, a promising future treatment for lupus.

Patent holder Corbus Pharmaceuticals is putting the drug, branded Resunab, through its clinical paces.

Ajulemic acid (AJA, CT‐3, IP‐751, JBT‐101, anabasum) is a first‐in‐class, synthetic, orally active, cannabinoid‐derived drug that preferentially binds to the CB2 receptor and is non psychoactive.

In preclinical studies, and in Phase 1 and 2 clinical trials, AJA showed a favorable safety, tolerability, and pharmacokinetic profile. It also demonstrated significant efficacy in preclinical models of inflammation and fibrosis.

Promising Screening Tools Assessed for Cognitive Dysfunction in SLE

Promising Screening Tools Assessed for Cognitive Dysfunction in SLE

The Montreal Cognitive Assessment (MoCA) questionnaire is an easy-to-administer, inexpensive, effective screening tool that can identify patients with systemic lupus erythematosus (SLE) who might be at risk for cognitive dysfunction (CD) and might benefit from additional neuropsychiatric assessment, according to data published in Lupus.